GEORGE R BLUMENSCHEIN to Oligonucleotides
This is a "connection" page, showing publications GEORGE R BLUMENSCHEIN has written about Oligonucleotides.
Connection Strength
0.252
-
Motesanib and advanced NSCLC: experiences and expectations. Expert Opin Investig Drugs. 2011 Jun; 20(6):859-69.
Score: 0.087
-
A phase II, multicenter, open-label randomized study of motesanib or bevacizumab in combination with paclitaxel and carboplatin for advanced nonsquamous non-small-cell lung cancer. Ann Oncol. 2011 Sep; 22(9):2057-2067.
Score: 0.086
-
Phase 1b study of motesanib, an oral angiogenesis inhibitor, in combination with carboplatin/paclitaxel and/or panitumumab for the treatment of advanced non-small cell lung cancer. Clin Cancer Res. 2010 Jan 01; 16(1):279-90.
Score: 0.079